CPDA-1- anticoagulant citrate phosphate dextrose adenine solution

CPDA-1 by

Drug Labeling and Warnings

CPDA-1 by is a Prescription medication manufactured, distributed, or labeled by Fenwal, Inc., Fenwal International, Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

Precautions:

  • Upon removal of BLOOD-PACK™ unit from the clear plastic overwrap, visually inspect the unit.
  • Do not use the product if the in-line cannula is broken and/or anticoagulant is present in the sample pouch or in the tubing from the in-line cannula to the sample pouch and donor needle (see Figure 1). Note that condensation in the empty tubing of the BLOOD-PACK unit is expected as a result of the sterilization process.
  • Do not use unless the solutions are clear.
  • 1. Identify BLOOD-PACK unit using appropriate donor identification system.
  • 2. Donor scale
  • Adjust donor scale to desired collection weight.
  • Position primary container on the donor scale as far as possible below donor arm.
  • 3. Clamp donor tubing between the needle and Y-junction with hemostat. (This step can be performed prior to step 1 or 2.)
  • 4. Visually inspect the tubing from the in-line cannula to the sample pouch and donor needle, as well as the sample pouch to reconfirm that there is no anticoagulant present.
    Note: Ensure that the sample pouch remains below the donor’s arm.
  • 5. Following blood center procedures, apply pressure to donor’s arm and disinfect site of venipuncture.
  • 6. Remove needle cover per instructions below:
  • Holding the hub and cover near the tamper-evident seal, twist cover 1/4 turn to break seal.
  • Remove needle cover, being careful not to drag the cover across the needle point.
  • 7. Following blood center procedures, perform venipuncture, appropriately secure donor needle and/or tubing and release hemostat.
  • 8. When good blood flow is established, slide the DONORCARE™ needle guard over the needle hub into the engaged position. Leave the front third of the needle hub exposed for access. Stabilize the front of the needle guard to arm with tape. (see Figure 2)
    Note: In difficult collection conditions (e.g. slow blood flow), leave the needle guard disengaged behind the hub during collection. Engage the needle guard at the end of blood collection. Appropriately secure needle and/or tubing.
  • 9. Allow the sample pouch to fill with blood according to center procedure. Monitor blood flow into sample pouch.

    • Notes:

  • The sample pouch contains an average fill volume of approximately 53 mL with a maximum fill volume of approximately 60 mL when filled to capacity.
  • If less blood sample volume is required, the flow to the sample pouch may be stopped prior to completely filling the pouch. For example, in order to target a fill volume of approximately 40 mL, fill to the level indicated by the arrows in Figure 1. Ensure the pouch is hanging vertically.
  • The tube leading from the Y-junction to the sample pouch contains an additional volume of approximately 2 mL.

    • Precautions:

  • Do not elevate or squeeze the sample pouch as this could cause blood to backflow from the sample pouch into the collection system.
  • Once the sample pouch is filled to desired volume, complete steps 10 - 18 within approximately 4 minutes to avoid possible clot formation in the tubing and/or sample pouch.
  • 10. Close the blue clamp on tubing between the Y-junction and the sample pouch.
  • 11. Break the in-line cannula below the Y-junction in the donor tubing to the primary container allowing blood collection to proceed. To completely break the in-line cannula, grasp with both hands. Snap it at a 90° angle in one direction, and then bend it at a 90° angle in the opposite direction. Ensure the in-line cannula is completely broken and that the blood flows freely to the primary container.

    • Precaution: Failure to break the in-line cannula completely may result in restricted blood flow.

  • 12. Following blood center procedures, mix blood and anticoagulant in the primary container immediately and at several intervals during collection.
  • 13. Following blood center procedures, hermetically seal the tubing between the sampling site and the Y-junction to maintain sterility of the blood collection system prior to removing blood samples.

    • Warning:

  • Do not proceed with the remaining steps until the tubing leading to the sample pouch is hermetically sealed between the sampling site and the Y-junction. To maintain the whole blood collection container as a closed system, the tubing between the sample pouch and Y-junction must be hermetically sealed prior to inserting the access device into the sampling site. Failure to do so may lead to contamination of the whole blood collection.
  • 14. Insert the access device by pushing firmly into the sampling site until the membrane seal is penetrated.

    • Note: If the access device is assembled such that the outer barrel is screwed onto the Luer, make sure to rotate clockwise upon insertion to avoid barrel detaching from Luer.

  • 15. Open the cap on the access device (if applicable). Hold access device so that the sample pouch hangs down.
  • 16. Directly align the vacuum sample tube with the internal needle in the access device. Insert vacuum sample tube into device.
  • 17. Allow vacuum sample tube to fill with blood then remove from the access device.
  • 18. Repeat steps 16 and 17 until the desired number of vacuum sample tubes have been filled.

    • Notes:

  • If the access device needs to be replaced, use a hemostat to clamp the tubing between the sampling site and the sample pouch. Then, grasp base of sampling site with one hand and pull the access device out with the other hand. Firmly insert the new access device. Remove hemostat and continue sampling.
  • If the access device is assembled such that the outer barrel is screwed onto the Luer, make sure to rotate clockwise upon removal to avoid barrel detaching from Luer.
  • The access device can only be replaced one time.

    • Precaution: When replacing access device, be careful to avoid contact with any blood droplets on the Luer or sampling site. Discard used access device appropriately.

  • 19. Collect the appropriate volume based on BLOOD-PACK unit used.
    Note: The volume of anticoagulant is sufficient for the blood collection indicated on BLOOD-PACK unit ± 10%.

    • Precaution: Once the desired blood volume is collected, complete steps 20-23 within approximately 4 minutes to avoid possible clot formation in the tubing.

  • 20. Release pressure on the donor’s arm. If appropriate, apply hemostat to donor tubing between the needle and the Y-junction.
  • 21. Hermetically seal donor tubing near in-line cannula on side leading to the primary container.
  • 22. Withdrawal of Needle (see Figure 3)

    • Precaution: The needle guard must be held stationary while the needle is withdrawn into it.

  • a) Place folded sterile gauze over puncture site and hold in place with finger tip without exerting pressure.
  • b) Hold sides of needle guard near the front, between the index finger and thumb. Pull the tubing smoothly until the needle is locked into the needle guard.
  • c) Confirm the needle lock by:
  • Listen for the 2nd “click” as the needle is drawn into the needle guard.
  • Ensure the tubing cannot be pulled through the needle guard.
  • 23. Strip blood from donor tubing into primary container, mix and allow the tubing to refill; repeat once.
  • 24. Seal at X marks on donor tubing to provide numbered aliquots of anticoagulated blood for typing or crossmatching.

    • Note: Step 25 may be performed prior to step 23 or 24 if desired.

  • 25. Remove and discard the Sample Diversion System and needle guard into an appropriate biohazardous waste container following established procedures.

    • Component Preparation:

    Notes:

  • If a platelet concentrate is to be prepared, it should be separated from the red blood cells within 8 hours after blood collection.
  • Fresh frozen plasma should be separated from the red blood cells and placed in the freezer at -18° C or colder within 8 hours after blood collection.
  • 26. When processing a multiple BLOOD-PACK unit, centrifuge primary and secondary containers to prepare CPDA-1 red blood cells.
  • 27. Place primary container in plasma extractor and express plasma into the appropriate empty TRANSFER PACK™ container by releasing pressure plate and opening closure in tubing of primary container.
  • 28. When desired amount of plasma has been removed, clamp tubing between Y and plasma container.
  • 29. Seal transfer tubing in three places between the Y-connector and primary container. Cut middle seal being careful to avoid fluid splatter.
  • 30. For further processing with multiple BLOOD-PACK units, use standard component processing and storage techniques.
  • 31. Store suspended CPDA-1 whole blood/red blood cells between 1 and 6°C.
  • 32. Infuse CPDA-1 whole blood/red blood cells within 35 days of collection.
    Warning: Failure to achieve closed system processing conditions negates the extended storage claim and the red blood cell product must be transfused within 24 hours.

    • Store at Controlled Room Temperature.
    USP Definition of “Controlled Room Temperature”
    United States Pharmacopeia, General Notices.
    United States Pharmacopeial Convention, Inc.
    12601 Twinbrook Parkway, Rockville, MD

    Representative Product Drawing

    logo– Manufacturer

    FENWAL, BLOOD-PACK and TRANSFER PACK are trademarks of Fenwal, Inc.

    DONORCARE is a trademark of ITL Corporation.

    © 2010 Fenwal, Inc. All rights reserved.

    logo Fenwal, Inc
    Lake Zurich, IL 60047 USA

    Made in USA

    1-800-933-6925

    07-19-04-631 REV: A
    03/2010

  • PACKAGE/LABEL DISPLAY PANEL

    Code 4R3644

    12 Units

    Fenwal™

    Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1) BLOOD-PACK™ Unit

    Quadruple For Collection and Processing of 500 mL Blood
    Sample Diversion System, DONORCARE™ Needle Guard, 16 ga. Ultra Thin Wall Needle

    Rx only

    Each unit consists of a PL 146 Plastic primary container with 70 mL of CPDA-1 solution containing 2.23 g Dextrose (monohydrate) USP, 1.84 g Sodium Citrate (dihydrate) USP, 209 mg Citric Acid (anhydrous) USP, 155 mg Monobasic Sodium Phosphate (monohydrate) USP and 19.3 mg Adenine USP, pH may have been adjusted with sodium hydroxide; three empty 400 mL PL 146 Plastic TRANSFER-PACK™ containers.

    Sterile, non-pyrogenic fluid path.
    See instructions for use.

    Store at Controlled Room Temperature (refer to direction insert).

  • Open pouch by tearing across at notch.
  • Direct handling of product surfaces prior to extended storage in the foil pouch, may result in mold growth.
  • Unused units in open foil pouch may be kept up to 60 days by folding and securing open end of foil pouch to prevent possible loss of moisture, provided:
  • I) Units are not removed from foil pouch, or
  • II) Unused units removed from foil pouch are returned to the foil pouch within 12 hours. Units may be removed from the pouch and returned only once.
  • Units removed from the foil pouch (that are not returned to the pouch within 12 hours) must be used within 4 days (96 hours). Units out of the foil pouch for longer than 96 hours must be discarded.

    • FENWAL, BLOOD-PACK and TRANSFER-PACK are trademarks of Fenwal, Inc.

    DONORCARE is a trademark of ITL Corporation.

    logoFenwal, Inc.
    Lake Zurich, IL 60047 USA

    Made in USA

    07-28-05-613 REV: A

    Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1) BLOOD-PACK™ Unit label
  • INGREDIENTS AND APPEARANCE
    CPDA-1 
    anticoagulant citrate phosphate dextrose adenine solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0942-6312
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Dextrose Monohydrate (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK) Dextrose Monohydrate2.23 g  in 70 mL
    Trisodium Citrate Dihydrate (UNII: B22547B95K) (Anhydrous Citric Acid - UNII:XF417D3PSL) Anhydrous Citric Acid1.84 g  in 70 mL
    Anhydrous Citric Acid (UNII: XF417D3PSL) (Anhydrous Citric Acid - UNII:XF417D3PSL) Anhydrous Citric Acid209 mg  in 70 mL
    Sodium Phosphate, Monobasic, Monohydrate (UNII: 593YOG76RN) (PHOSPHATE ION - UNII:NK08V8K8HR) Sodium Phosphate, Monobasic, Monohydrate155 mg  in 70 mL
    Adenine (UNII: JAC85A2161) (Adenine - UNII:JAC85A2161) Adenine19.3 mg  in 70 mL
    Inactive Ingredients
    Ingredient NameStrength
    Sodium Hydroxide (UNII: 55X04QC32I)  
    Water (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0942-6312-0470 mL in 1 BAG; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDABN77042003/01/2007
    Labeler - Fenwal, Inc. (794519020)
    Establishment
    NameAddressID/FEIBusiness Operations
    Fenwal International, Inc.091164590MANUFACTURE(0942-6312)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.